The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Cortical remyelination: A new target for repair therapies in multiple sclerosis
Open accessAbstract
OBJECTIVE: Generation and differentiation of new oligodendrocytes in demyelinated white matter is the best described repair process in the adult human brain. However, remyelinating capacity falters with age in patients with multiple sclerosis (MS). Because demyelination of cerebral cortex is extensive in brains from MS patients, we investigated the capacity of cortical lesions to remyelinate and directly compared the extent of remyelination in lesions that involve cerebral cortex and adjacent subcortical white matter. METHODS: Postmortem brain tissue from 22 patients with MS (age 27-77 years) and 6 subjects without brain disease were analyzed. Regions of cerebral cortex with reduced myelin were examined for remyelination, oligodendrocyte progenitor cells, reactive astrocytes, and molecules that inhibit remyelination. RESULTS: New oligodendrocytes that were actively forming myelin sheaths were identified in 30 of 42 remyelinated subpial cortical lesions, including lesions from 3 patients in their 70s. Oligodendrocyte progenitor cells were not decreased in demyelinated or remyelinated cortices when compared to adjacent normal-appearing cortex or controls. In demyelinated lesions involving cortex and adjacent white matter, the cortex showed greater remyelination, more actively remyelinating oligodendrocytes, and fewer reactive astrocytes. Astrocytes in the white matter, but not in cortical portions of these lesions, significantly upregulate CD44, hyaluronan, and versican, molecules that form complexes that inhibit oligodendrocyte maturation and remyelination. INTERPRETATION: Endogenous remyelination of the cerebral cortex occurs in individuals with MS regardless of disease duration or chronological age of the patient. Cortical remyelination should be considered as a primary outcome measure in future clinical trials testing remyelination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Although OPCs represent an available pool to replace lost oligodendrocytes and myelin, replacement is limited, particularly in cortical lesions (Chang et al. 2012).”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Chang et al. 2012
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies in human post-mortem tissue and experimental models suggested that remyelination after a demyelinating insult is more efficient in the cerebral cortex compared to the white matter.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In patients with multiple sclerosis, remyelination has been observed in both white and grey matter and found to be more efficient in the cortex.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Studies in human tissue and experimental models suggest that numerical and functional differences in oligodendrocyte lineage cells, as well as e.g. the phenotype of reactive astrogliosis, including a lower expression of CD44, versican and hyaluronan in the cortex, may play a role.15”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Noseworthy, J. H., Lucchinetti, C. F., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 3,016
CD44: From adhesion molecules to signalling regulators
Ponta, H., Sherman, L. S., & Herrlich, P. A. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1004 · Cited by 2,458
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Remyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403
Self-citationPremyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991
Self-citationKuhlmann, T., Miron, V., Cuo, Q., Wegner, C., Antel, J., & Bruck, W. (2008) · Brain · doi:10.1093/brain/awn096 · Cited by 864
Remyelination is extensive in a subset of multiple sclerosis patients
Patrikios, P., Stadelmann, C., Kutzelnigg, A., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., Bruck, W., Lucchinetti, C., & Lassmann, H. (2006) · Brain · doi:10.1093/brain/awl217 · Cited by 807
Cortical lesions in multiple sclerosis
Kidd, D., Barkhof, F., McConnell, R., Algra, P. R., Allen, I. V., & Revesz, T. (1999) · Brain · doi:10.1093/brain/122.1.17 · Cited by 766
Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients
Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D., & Mørk, S. J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.7.723 · Cited by 757
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–216 of 216
Вивчення процесів регенерації мієліну – від експерименту до клініки
Нефьодов, О. О., Kalbus, O. I., Макаров, С. О., Родіонов, В., Крижановський, І., Гладких, Н. О., Сіразетдінова, Г., Власова, К., & Markhon, N. A. (2023) · Pharmacology and Drug Toxicology · doi:10.33250/17.03.157
Tunley, S. (2024) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.25201913
The immunology and pathophysiology of multiple sclerosis
Saez-Calveras, N., & Stüve, O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95739-7.00020-4
Epigenomic regulation of human oligodendrocyte myelination properties – relation to age and lineagePreprint
Mohammadnia, A., Dansu, D. K., Cui, Q., Yaqubi, M., Dudley, R., Stratton, J. A., Zandee, S., Kennedy, T. E., Srour, M., Casaccia, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.04.674347
Lazzarotto, A. (2023) · theses.fr (ABES) · doi:10.70675/245e2c82zb2bdz4b9dzbd16zc18dbdc9732b
Imaging myelin content changes: A bridge between tissue and clinics
Galbusera, R., Stadelmann, C., & Granziera, C. (2026) · Revue Neurologique · doi:10.1016/j.neurol.2026.03.011
Myelin Repair as a Neuroprotective Strategy for Multiple Sclerosis: From Bench to Bedside
Battah, T., Mastorodemos, V., Struecker, E., Mitsikostas, D. D., & Papadopoulos, D. (2026) · Medicina · doi:10.3390/medicina62061183
A novel small molecule remyelination therapy for multiple sclerosis
Yang, Y., Bai, B., Knutsen, L. J. S., Hamlyn, R. J., Cui, Q., Antel, J. P., Macklin, W. B., Medicetty, S., & Trapp, B. D. (2026) · npj Drug Discovery. · doi:10.1038/s44386-026-00060-7
Self-citationNakagawa, Y., & Yamada, S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06217-9
Metadata
- Authors
- Chang, A., Staugaitis, S. M., Dutta, R., Batt, C. E., Easley, K. E., Chomyk, A. M., Yong, V. W., Fox, R. J., Kidd, G. J., & Trapp, B. D.
- Affiliations
- Cleveland Clinic (US)
- University of Calgary (CA)
- Corresponding author
- Trapp, Bruce D.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-10-17
- Volume
- 72
- Issue
- 6
- Pages
- 918-926
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC3535551
- OpenAlex
- W2061522969
- Cited by
- 216
- References
- 42
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 10 · 2023: 19 · 2022: 22 · 2021: 16 · 2020: 18 · 2019: 23 · 2018: 16 · 2017: 11 · 2016: 16 · 2015: 16 · 2014: 13 · 2013: 13 · 2012: 2
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Multiple Sclerosis Society
- Cleveland Clinic
- National Institutes of Health (UL1TR000439)
- University of California, Davis
- National Institute of Neurological Disorders and Stroke (NS38867, P50NS038667)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- multiple sclerosis, demyelination, oligodendrocyte precursor cells, reactive astrocytes, CD44, hyaluronic acid, versican, oligodendrocyte maturation, white matter lesions, remyelination therapy
- MeSH terms
- Chondroitin Sulfate Proteoglycan 4, Adult, Aged, Antigens, Cerebral Cortex, Demyelinating Diseases, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Multiple Sclerosis, Myelin Sheath, Nerve Fibers, Myelinated, Oligodendroglia, Postmortem Changes, Proteoglycans, Regeneration, RNA, Messenger, Hyaluronan Receptors, Myelin Proteolipid Protein, Adaptor Proteins, Signal Transducing, Adult Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
